WASHINGTON — The head of the brand drug lobby used an in-person health insurance industry conference to blame insurers for making people pay too much for drugs.
America’s Health Insurance Plans CEO Matt Eyles, interviewing PhRMA President Stephen Ubl, asked for examples of policies that would benefit both industries. Ubl responded by suggesting that insurers lower cost sharing for drugs. He said spending on drugs rose about 1% last year and that the rebates that insurers get from drugmakers continued to go up “exponentially.”
“And you would think, OK, if those two things are true … you would think that out-of-pocket costs for consumers would also be going down, and the opposite is true,” Ubl said.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect